Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
about
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyHyperglycemia induced by pasireotide in patients with Cushing's disease or acromegalyTargeting kinase signaling pathways with constrained peptide scaffolds.Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomasEffects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: a Single‐Center, Phase I, Randomized, Four‐Way Crossover StudyCombination of Klinefelter Syndrome and Acromegaly: A Rare Case Report.Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.AACE/ACE disease state clinical review: diagnosis and management of midgut carcinoidsPasireotide in Acromegaly: A Review.Long-term health outcomes of adults with McCune-Albright syndrome.Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitroEffect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats.How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.
P2860
Q26796357-8CFF3C92-F7D2-4740-A9C0-8A2A5F851F57Q28069603-AF97809C-B3F0-4307-A449-18B2AFB299A5Q30398451-3703F0A0-331E-4B34-9B38-88A0DD9A872DQ34658946-F9D8517F-9010-4D29-ABCF-8B2B4056D19BQ34745395-3D6BC303-4A7C-431C-BE5F-F4C22B972424Q37206376-D4A57A3F-3203-451E-BADE-60B9A6244E6DQ38233686-F7C521F6-EA4F-42A7-8CC4-16EE21A65233Q38472683-86E55DEB-7219-4F67-B973-0C899D9955C6Q38504642-029D4859-7C43-4481-8F53-96EC1F13C95EQ39429965-2E837675-886D-49A1-8037-C122AA2B61F6Q41548629-545FAF7D-759B-42F8-B065-C764DCBE73D6Q54144943-27F23FBD-B186-4F4E-AF9B-B05EE842DE14Q54939988-DAA9A492-4283-4B3E-8520-9408C8536816
P2860
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-term efficacy and safety ...... ter, Phase II extension study.
@en
Long-term efficacy and safety ...... ter, Phase II extension study.
@nl
type
label
Long-term efficacy and safety ...... ter, Phase II extension study.
@en
Long-term efficacy and safety ...... ter, Phase II extension study.
@nl
prefLabel
Long-term efficacy and safety ...... ter, Phase II extension study.
@en
Long-term efficacy and safety ...... ter, Phase II extension study.
@nl
P2093
P2860
P1433
P1476
Long-term efficacy and safety ...... ter, Phase II extension study.
@en
P2093
Andrew J Farrall
Ariel Barkan
Christophe De Block
David Kleinberg
Gareth Hughes
Jochen Schopohl
Karina Hermosillo Reséndiz
Matthieu Ruffin
Philippe Caron
P2860
P2888
P304
P356
10.1007/S11102-013-0478-0
P577
2014-04-01T00:00:00Z